Rigolin, Gian Matteo
Olimpieri, Pier Paolo http://orcid.org/0000-0001-7934-9034
Summa, Valentina
Celant, Simone
Scarfò, Lydia http://orcid.org/0000-0002-0844-0989
Tognolo, Lucia
Ballardini, Maria Pia
Urso, Antonio
Sessa, Mariarosaria http://orcid.org/0000-0002-0519-7645
Gambara, Silvia
Cura, Francesca
Fortini, Monica
Ghia, Paolo http://orcid.org/0000-0003-3750-7342
Cuneo, Antonio
Russo, Pierluigi
Funding for this research was provided by:
Associazione Italiana per la Ricerca sul Cancro (21198 (5 per mille 2018), 27556 (IG 2022))
Università degli Studi di Ferrara (FAR 2020, 2021, 2022, FAR 2022 2021 2022)
Associazione Italiana Contro le Leucemie - Linfomi e Mieloma
Article History
Received: 23 March 2023
Revised: 12 May 2023
Accepted: 5 June 2023
First Online: 28 June 2023
Competing interests
: GMR received honoraria for participation to speaker’s bureau from Abbvie, Astra Zeneca, Janssen. LS received honoraria for advisory board participation from AbbVie, AstraZeneca, BeiGene, and Janssen and travel grants from Beigene and Janssen; she is on the speakers bureau for Octapharma. AC received honoraria for participation to speaker’s bureau and advisory board from Abbvie, Astra Zeneca, Beigene, Janssen. PG received research support from AbbVie, AstraZeneca, Janssen and honoraria from AbbVie, AstraZeneca, BeiGene, BMS, Janssen, Lilly/Loxo Oncology, MSD, Roche. PPO, VS, SC, LT, MPB, AU, MS, SG, FC, MF and PR have no conflict of interests.